[Translation] A randomized, open-label, single-dose, two-sequence, two-period, fasting bioequivalence study of bilastine tablets (20 mg) produced by Xi'an Taiji Pharmaceutical Co., Ltd. and bilastine tablets (20 mg) produced by FAES FARMA, S.A. in healthy Chinese subjects
以西安太极药业有限公司生产的比拉斯汀片(规格:20 mg)为受试制剂,FAES FARMA, S.A.生产的比拉斯汀片(规格:20 mg)为参比制剂,考察两制剂在空腹状态下单次给药的药代动力学参数及相对生物利用度,评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性。
[Translation] Bilastine tablets (specification: 20 mg) produced by Xi'an Taiji Pharmaceutical Co., Ltd. were used as the test preparation, and Bilastine tablets (specification: 20 mg) produced by FAES FARMA, S.A. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations after single administration under fasting conditions were investigated to evaluate whether the two preparations were bioequivalent. At the same time, the safety of the two preparations in healthy humans was evaluated.